Summary & Overview

HCPCS G9845: Anti-EGFR Monoclonal Antibody Therapy

HCPCS Level II code G9845 designates administration of anti-EGFR monoclonal antibody therapy, a targeted biologic infusion used in oncology and select specialty care. Nationally, coding for targeted monoclonal antibody administration matters for clinical documentation, payer adjudication, and accurate capture of therapy utilization and outcomes. Clear use of G9845 ensures services are recorded for therapy tracking and reimbursement workflows.

Payors covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for anti-EGFR monoclonal antibody therapy, the typical site-of-service profile, and the payer landscape relevant to this code. The publication outlines benchmarks and billing considerations, highlights policy updates affecting biologic infusion coding, and provides clinical context for when this therapy is used.

The content is intended for revenue cycle leaders, oncology clinic managers, and policy analysts seeking a national perspective on coding and payer coverage implications for targeted EGFR-directed monoclonal antibody administration. Data not available in the input are noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareG9845HCPCS Level IIanti-EGFRmonoclonal antibodyinfusion therapyoncologyoutpatient infusionbiologic therapy

Billing Code Overview

HCPCS Level II code G9845 indicates that a patient received anti-EGFR monoclonal antibody therapy. This code represents administration of targeted biologic therapy aimed at inhibiting the epidermal growth factor receptor (EGFR) pathway.

Service type: Infusion/biologic therapy
Typical site of service: Outpatient infusion center or hospital outpatient department

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A patient with advanced or metastatic solid tumor exhibiting epidermal growth factor receptor (EGFR) overexpression or activating EGFR mutation receives an anti-EGFR monoclonal antibody infusion as part of systemic targeted therapy. Typical patients are adults referred to an outpatient oncology infusion center or hospital infusion suite after confirmatory tumor testing (immunohistochemistry, fluorescence in situ hybridization, or molecular testing) demonstrates eligibility. The oncology advanced practice provider or medical oncologist documents indication, prior therapy, and consent; nursing completes infusion consents, baseline vital signs, and pre-medications (antihistamine and steroid per protocol). The treatment encounter includes medication preparation by pharmacy (verifying dose by weight or body surface area), verification of patient identity and allergy status, IV placement or assessment of central venous access device, administration of the anti-EGFR monoclonal antibody over the recommended infusion time, monitoring for infusion reactions, and post-infusion observation prior to discharge. Typical sites of service are outpatient infusion centers, physician office-based infusion suites, or hospital outpatient departments. Billing uses HCPCS Level II code G9845 to indicate the patient received anti-EGFR monoclonal antibody therapy; clinical documentation should include indication, agent name, dose, lot number, date and time of administration, route, infusion duration, site of service, and any infusion-related events.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	Use when work or resources substantially exceed typical for administration due to complexity (document justification).
`23`	Unusual anesthesia	Use if significant anesthesia unrelated to the drug administration is required for the infusion.
`52`	Reduced services	Use when the infusion is partially reduced or discontinued for clinical reasons.
`53`	Discontinued procedure	Use if the infusion is started but terminated before completion for patient safety.
`54`	Surgical care only	Not typically used for infusion; include only if a concurrent surgical service is billed separately.
`55`	Postoperative management only	Not typically used; include only for follow-up global period billing separation.
`56`	Preoperative management only	Rare for infusion; include only if pre-op management is billed separately.
`62`	Two surgeons	Use when two qualified clinicians are required for administration due to clinical complexity.
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist services for Medicare	Use when a covered non-physician practitioner furnished the service under applicable rules.
`CO`	Medicaid/State program payment adjustment	Use when payment is adjusted per state Medicaid billing instructions.
`CQ`	Service furnished by a registered nurse practitioner, physician assistant, or clinical nurse specialist for non-Medicare payors	Use when reporting non-physician practitioner involvement per payor requirements.
`FX`	Distinct procedural service	Use when the infusion service is distinct from other procedures on the same day and meets distinct procedural criteria.
`QK`	Medical direction of two, three, or four concurrent anesthesia procedures	Use only if anesthesia services are billed and physician direction criteria are met.
`QX`	CRNA service with physician absence	Use when a certified registered nurse anesthetist furnishes anesthesia without physician present (if applicable).

Taxonomy Code	Specialty	Notes
`207RG0200X`	Medical Oncology	Primary specialty ordering and managing anti-EGFR therapy.
`207RH0002X`	Hematology-Oncology	Specialists who commonly prescribe and supervise systemic monoclonal antibody therapy.
`363L00000X`	Infusion Therapy	Nursing and infusion specialists administering biologic agents.
`207Q00000X`	Radiation Oncology	Sometimes involved in multidisciplinary care when combined modality therapy is used.
`286N00000X`	Oncology Nursing	Providers responsible for infusion administration and monitoring.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C34.90`	Malignant neoplasm of unspecified part of unspecified bronchus or lung	EGFR-targeted monoclonal antibodies are used in subsets of non-small cell lung cancer with EGFR alterations.
`C50.912`	Malignant neoplasm of unspecified site of left female breast	EGFR pathway alterations may be relevant in some breast cancer subtypes considered for targeted therapy.
`C18.9`	Malignant neoplasm of colon, unspecified	EGFR inhibitors are used in selected metastatic colorectal cancers without RAS mutations.
`C71.9`	Malignant neoplasm of brain, unspecified	Rarely, EGFR-targeted therapies are considered in select central nervous system tumors with actionable EGFR alterations.
`C80.1`	Malignant (primary) neoplasm, unspecified	Used when primary site is unknown but targeted anti-EGFR therapy is indicated based on molecular profiling.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, intravenous infusion, each additional hour (List separately in addition to primary infusion code)	Used for additional infusion time when anti-EGFR antibody infusion exceeds the base time billed by the primary infusion code.
`96365`	Intravenous infusion, therapeutic, prophylactic, diagnostic; initial, up to 1 hour	Often used for the initial hour of infusion for certain IV-administered biologics when billed by CPT instead of HCPCS.
`96366`	Intravenous infusion, each additional hour (List separately in addition to primary infusion code)	Billed when infusion extends beyond the initial hour for prolonged administration.
`96415`	Chemotherapy administration, each additional hour (up to 8 hours)	Alternative code for extended IV infusion time for oncology biologics as applicable.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Used for any pre-medication injections (antihistamines, steroids) given prior to infusion.
`36415`	Collection of venous blood by venipuncture	Performed for baseline labs, drug monitoring, or post-infusion testing associated with therapy.